Non-specific pharmacological inhibition of the histone deacetylase (HDAC) family of enzymes has largely beneficial effects in a variety of diverse contexts including cancer, cognitive function, and neurodegeneration. This review will discuss the role of individual HDAC isoforms in brain function during development and in the adult. Importantly class I and class II HDACs exhibit distinct cellular and subcellular expression patterns and utilize different signaling pathways to influence their substrates. Moreover, dissociable phenotypic outcomes emerge following manipulation of individual HDACs in the brain. To date, pharmacological inhibitors capable of targeting individual HDACs have proven difficult to develop, an obstacle that must be overcome to unlock the substantial clinical promise of manipulating endogenous HDAC isoforms in the central nervous system.
Introduction
Histone deacetylases (HDACs) are an evolutionarily ancient enzyme family that regulate activity of their substrates by removing acetyl groups from lysine residues (Gregoretti et al., 2004; Hildmann et al., 2007) . Histone deacetylases are so named based on their ability to govern chromatin structural dynamics by deacetylating N-terminal lysine residues within the protruding tails of histone proteins, a modification associated with repression of gene transcription, however, the acetylation/deacetylation reaction occurs in at least 80 proteins and HDACs can act on many substrates (Kouzarides, 2000; Glozak et al., 2005; Ocker, 2010) . Alternatively, the histone acetyltransferases (HATs), by acetylation of histone tails, neutralize their positive charge thereby relaxing chromatin structure due to greater electrostatic repulsion from negatively charged DNA, a modification associated with transcriptional activation (Feng et al., 2007; Haberland et al., 2009a) . In a provocative recent study, Wang et al. (2009) found that both HATs and HDACs are found at transcribed regions of active genes, and suggested that HDACs function to "reset" the conformational state of chromatin by removing acetylation at active genes (Wang et al., 2009) .
Primarily through the use of non-specific, "pan-" HDAC inhibitors which inhibit many or all HDACs, HDACs have been implicated in diverse biological processes, including but not limited to, tissue specific developmental programming, apoptosis, synaptogenesis, cognition, cancer, and neurodegenerative disease (Bolger and Yao, 2005; Minucci and Pelicci, 2006; Hildmann et al., 2007; Barrett and Wood, 2008; Akhtar et al., 2009; Brunmeir et al., 2009; Chuang et al., 2009; Haberland et al., 2009a) . Biological functions of individual HDACs have been difficult to determine due to the lack of specific pharmacological inhibitor compounds for particular HDACs. Moreover, constitutive knockout (KO) of many of the individual HDACs are lethal, underscoring the vital role of these enzymes in normal development, but rendering the use of constitutive KO models unsuitable for study in the adult. Conditional KO and small-interfering RNA (siRNA) strategies are now being employed to study the unique functional profiles of individual HDAC isoforms, with the obvious benefit that the animals are viable and knockdown can be made in a temporal-and anatomical region-specific manner.
Attention has recently been lavished upon the HDACs due to the efficacy of certain HDAC inhibitor compounds in treating some forms of cancer. To date two HDAC inhibitors have been approved for cutaneous T-cell lymphoma (vorinostat and depsipeptide) and several are in phase II or III clinical trials for cervical and ovarian cancer (Minucci and Pelicci, 2006; Duvic and Vu, 2007; Kristensen et al., 2009) . Beyond cancer, HDAC inhibitors are recognized for their ability to influence a wide spectrum of neurodevelopmental and neurophysiological processes. For example, HDAC inhibition is neuroprotective in in vitro and in vivo models of neurotoxicity and degeneration, and can improve cognitive function following traumatic brain injury or neurodegeneration in animal models (Ferrante et al., 2003; Petri et al., 2006; Avila et al., 2007; Dompierre et al., 2007; Fischer et al., 2007; Chuang et al., 2009; Dash et al., 
